carbamazepine has been researched along with Bone Loss, Osteoclastic in 7 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the markers of bone turnover in epilepsy patients in the different stages of the pubertal growth before and after the beginning of carbamazepine (CBZ) monotherapy." | 3.71 | Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. ( Chiarelli, F; Greco, R; Latini, G; Morgese, G; Verrotti, A, 2002) |
| "To examine bone development in children and adolescents who have uncomplicated idiopathic epilepsy and had received monotherapy with carbamazepine or valproic acid for at least 1 year." | 3.71 | Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. ( Herkenrath, P; Rauch, F; Rieger-Wettengl, G; Schauseil-Zipf, U; Schoenau, E; Stabrey, A; Tutlewski, B, 2001) |
| "Carbamazepine was prescribed at normal dosages (16." | 2.71 | Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. ( Attilakos, A; Dimou, S; Garoufi, A; Katsarou, E; Mastroyianni, S; Skardoutsou, A; Voudris, KA, 2005) |
| "Markers of bone formation and bone resorption were determined in serum and urine." | 1.31 | Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. ( Becker, A; Feldkamp, J; Scharff, D; Scherbaum, WA; Witte, OW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verrotti, A | 2 |
| Greco, R | 1 |
| Latini, G | 1 |
| Morgese, G | 1 |
| Chiarelli, F | 2 |
| Voudris, KA | 1 |
| Attilakos, A | 1 |
| Katsarou, E | 1 |
| Garoufi, A | 1 |
| Dimou, S | 1 |
| Skardoutsou, A | 1 |
| Mastroyianni, S | 1 |
| Mintzer, S | 1 |
| Boppana, P | 1 |
| Toguri, J | 1 |
| DeSantis, A | 1 |
| Matricardi, S | 1 |
| Manco, R | 1 |
| Välimäki, MJ | 1 |
| Tiihonen, M | 1 |
| Laitinen, K | 1 |
| Tähtelä, R | 1 |
| Kärkkäinen, M | 1 |
| Lamberg-Allardt, C | 1 |
| Mäkelä, P | 1 |
| Tunninen, R | 1 |
| Feldkamp, J | 1 |
| Becker, A | 1 |
| Witte, OW | 1 |
| Scharff, D | 1 |
| Scherbaum, WA | 1 |
| Rieger-Wettengl, G | 1 |
| Tutlewski, B | 1 |
| Stabrey, A | 1 |
| Rauch, F | 1 |
| Herkenrath, P | 1 |
| Schauseil-Zipf, U | 1 |
| Schoenau, E | 1 |
1 trial available for carbamazepine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes.
Topics: Alkaline Phosphatase; Anticonvulsants; Bone Resorption; Carbamazepine; Child; Child, Preschool; Epil | 2005 |
6 other studies available for carbamazepine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Biomarkers; Bone Diseases, Metabolic; Bone Resorpti | 2002 |
Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Anticonvulsants; Biomarkers; Bone and Bones; Bone Res | 2006 |
Bone metabolism and vitamin D levels in carbamazepine-treated patients.
Topics: Anticonvulsants; Bone and Bones; Bone Development; Bone Resorption; Carbamazepine; Dose-Response Rel | 2006 |
Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
Topics: Absorptiometry, Photon; Adult; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption | 1994 |
Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.
Topics: Absorptiometry, Photon; Adult; Amino Acids; Anticonvulsants; Bone Density; Bone Resorption; Carbamaz | 2000 |
Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine.
Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Anticonvulsants; Biomarkers; Bone Density; Bone Resor | 2001 |